Tomas G Lyons1, Maura N Dickler1,2, Elizabeth E Comen3. 1. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, 300 E. 66th Street, New York, NY, 10065, USA. 2. Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY, USA. 3. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, 300 E. 66th Street, New York, NY, 10065, USA. comene@mskcc.org.
Abstract
PURPOSE OF REVIEW: The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer. RECENT FINDINGS: The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal. Clinical studies suggest response rates between 5 and 10% in pretreated patients and roughly 20-25% for untreated advanced TNBC. However, in the small subset of patients who do respond, the response is often durable. More encouraging results have been reported with their use in combination with chemotherapy in the neoadjuvant setting. Larger phase III studies are underway to confirm these earlier findings. An immune-directed therapeutic approach for the management of BC is underway, and it is likely that combination therapy will be required to achieve a level of efficacy worthy of use in the BC treatment paradigm. These agents are not without both economic and clinical toxicity; therefore, it is imperative that we identify patients most likely to benefit from these therapies through well-designed biologically plausible clinical studies and by evaluating novel combinatorial approaches with informative biomarker driven correlative studies.
PURPOSE OF REVIEW: The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer. RECENT FINDINGS: The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal. Clinical studies suggest response rates between 5 and 10% in pretreated patients and roughly 20-25% for untreated advanced TNBC. However, in the small subset of patients who do respond, the response is often durable. More encouraging results have been reported with their use in combination with chemotherapy in the neoadjuvant setting. Larger phase III studies are underway to confirm these earlier findings. An immune-directed therapeutic approach for the management of BC is underway, and it is likely that combination therapy will be required to achieve a level of efficacy worthy of use in the BC treatment paradigm. These agents are not without both economic and clinical toxicity; therefore, it is imperative that we identify patients most likely to benefit from these therapies through well-designed biologically plausible clinical studies and by evaluating novel combinatorial approaches with informative biomarker driven correlative studies.
Entities:
Keywords:
Breast cancer; Checkpoint inhibitors; Immunotherapy; PD-1; PD-L1; Triple-negative breast cancer
Authors: Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2017-12-07 Impact factor: 41.316
Authors: Stephen J Luen; Roberto Salgado; Stephen Fox; Peter Savas; Jennifer Eng-Wong; Emma Clark; Astrid Kiermaier; Sandra M Swain; Jose Baselga; Stefan Michiels; Sherene Loi Journal: Lancet Oncol Date: 2016-12-07 Impact factor: 41.316
Authors: Camilo Adem; Cheryl L Soderberg; Julie M Cunningham; Carol Reynolds; Thomas J Sebo; Stephen N Thibodeau; Lynn C Hartmann; Robert B Jenkins Journal: Int J Cancer Date: 2003-11-20 Impact factor: 7.396
Authors: Hannah Reimann; Andrew Nguyen; J Zachary Sanborn; Charles J Vaske; Stephen C Benz; Kayvan Niazi; Shahrooz Rabizadeh; Patricia Spilman; Andreas Mackensen; Matthias Ruebner; Alexander Hein; Matthias W Beckmann; Edith D van der Meijden; Judith Bausenwein; Sascha Kretschmann; Marieke Griffioen; Jeffrey Schlom; James L Gulley; Karin L Lee; Duane H Hamilton; Patrick Soon-Shiong; Peter A Fasching; Anita N Kremer Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751